An observational prospective cohort study of incidence and outcome of streptococcus pneumoniae and hemophilus influenzae infections in adult solid organ transplant recipients

Research output: Contribution to journalJournal articleResearchpeer-review

Documents

Background: Streptococcus pneumoniae (S. pneumoniae) and Hemophilus influenzae (H. influen-zae) are among the main vaccine-preventable bacterial infections in immunocompromised individuals including solid organ transplant (SOT) recipients. There is a lack of information about incidence and outcomes of these infections in SOT recipients. Methods: We determined the incidence of S. pneumoniae and H. influenzae, the related hospitalization, and 30-and 180-days mortality in a large cohort of 1182 adult SOT recipients. We calculated 95% confidence intervals (CI) of incidence rate (IR) using Byar’s approximation to the Poisson distribution. Results: The overall IR of S. pneumoniae and H. influenzae were 1086 (95% CI, 796–1448) and 1293 (95% CI, 974–1687) per 100,000 person-years of follow-up (PYFU), respectively. The IR of invasive infections were 76 (95% CI, 21–202) and 25 (95% CI, 2.3–118) per 100,000 PYFU, respectively. Hospital admission was required in >50%, 30-days mortality was 0, and 180-days mortality was 8.8% and 4.5% after S. pneumoniae and H. influenzae infections, respectively. Conclusions: The IR of invasive S. pneumoniae and H. influenzae infections in SOT recipients were much higher than reports from the general population in Denmark. Furthermore, a large proportion of infected SOT recipients were hospitalized. These findings highlight the need for further studies to assess uptake and immunogenicity of vaccines against S. pneumoniae and H. influenzae in SOT recipients.

Original languageEnglish
Article number1371
JournalMicroorganisms
Volume9
Issue number7
Number of pages10
ISSN2076-2607
DOIs
Publication statusPublished - Jul 2021

Bibliographical note

Funding Information:
Conflicts of Interest: O.R. received a grant from The Research Foundation of Rigshospitalet; S.S.S. reported other non-financial relations with Alexion, Hansa Biopharma, and Corline Biomedical, outside the submitted work; M.P. received a grant from Roche, non-financial support from Boehringer Ingelheim, personal fees from Mallinckrodt, Novartis, GSK, and Astra-Zeneca not related to this work; F.G. received personal fees from Abbott, Novartis, Boehringer-Ingelheim, Orion Pharma, Pfizer, and AstraZeneca and had other financial relationship with Corvia not related to this work; M.G. received a grant from Augustinus Foundation not related to this work; S.D.N. received unrestricted research grants from Novo Nordisk Foundation and Independent Research Fund (FSS); D.L.M., J.K., M.H., A.R. and Z.B.H. declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Funding Information:
Funding: This work was supported by the Novo Nordisk Foundation, Independent Research Fund (FSS), the Danish National Research Foundation (grant number DNRF126), and the Research Foundation of Rigshospitalet.

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

    Research areas

  • Hemophilus influenzae, Hospitalization, Incidence, Invasive pneumococcal diseases, Mortality, Organ transplant, Streptococcus pneumoniae

Number of downloads are based on statistics from Google Scholar and www.ku.dk


No data available

ID: 273067946